AbbVie Terminates Development Agreement with CollPlant; Company Announces 50% Workforce Reduction

On April 9, 2026, CollPlant Biotechnologies was notified by Allergan Industrie SAS, an AbbVie company, that it is terminating their 2021 development agreement for dermal and soft tissue fillers. The termination will become effective on June 8, 2026. In response to the loss of this major partnership, CollPlant is implementing a significant restructuring plan, including a 50% workforce reduction and updated expense forecasting to extend its cash runway into Q4 2026. Despite the termination, management expressed optimism, stating they are actively pursuing new strategic partnerships for their rhCollagen technology and are in discussions with several Tier 1 corporations. The company remains focused on its core programs, including regenerative breast implants and 3D bioprinting bioinks. CollPlant also aims to develop a new portfolio of regenerative fillers independently or with new partners, with a goal to initiate clinical trials within the next two years.